Aktienanalyse zu Quanterix Corp (QTRX)QTRXQuanterix Corp

Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Quanterix Corp (QTRX) is not a good buy right now due to significant financial challenges and negative market sentiment. The current price is $2.64, which is down 58.94% year-to-date. The company has a low RSI of 35.76, indicating potential oversold conditions, but this is coupled with a weak forward P/E ratio of 0, reflecting a lack of earnings expectations. Furthermore, analysts have downgraded their price targets significantly, with the latest being $3, which suggests limited upside potential from the current price. The main risk is the company's recent revenue guidance cut, which was lowered from $169 million to a range of $142 million to $148 million for 2026, highlighting ongoing market weaknesses and execution challenges.

4 analysts cover QTRX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 7.50.